Joyce Cheng - Concepedia

Author

Joyce Cheng

United States Food and Drug Administration ORCID

Also Known As

J Cheng, J. Cheng, J.D. Cheng, Jianyang Chen, Joyce CHENG, Joyce Cheng, Wolff, S.C.

Publications

1.6K

Citations

H-Index

Concepts

All Affiliations

United States Food and Drug Administration Center for Drug Evaluation and Research

About

Joyce Cheng is an author at United States Food and Drug Administration specializing in oncology, medicine, and cancer therapeutics.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	8	8	641
2	Health Sciences	4	4	228
3	Public Health	1	1	40
4	Diagnostic Sciences	1	1	10
5	Epidemiology	1	1	40

Joyce Cheng

Publications

1.3K

Citations

H-Index

Page 1

	Year	Citations
CDK4/6 inhibitor treatment for patients with hormone receptor-positive, HER2-negative, advanced or metastatic breast cancer: a US Food and Drug Administration pooled analysis Jennifer Gao, Joyce Cheng, Erik Bloomquist, The Lancet Oncology Metastatic Breast CancerBreast OncologyMedicinePharmacologyBreast Cancer	2019	288
FDA Approval Summary: Pembrolizumab for the First-line Treatment of Patients with MSI-H/dMMR Advanced Unresectable or Metastatic Colorectal Carcinoma Sandra J. Casak, Leigh Marcus, Lola A. Fashoyin‐Aje, Clinical Cancer Research	2021	167
FDA Approval Summary: Accelerated Approval of Sacituzumab Govitecan-hziy for Third-line Treatment of Metastatic Triple-negative Breast Cancer Sakar Wahby, Lola A. Fashoyin‐Aje, Christy Osgood, Clinical Cancer Research	2020	142
U.S. Food and Drug Administration Approval: Neratinib for the Extended Adjuvant Treatment of Early-Stage HER2-Positive Breast Cancer Harpreet Singh, Amanda J. Walker, Laleh Amiri‐Kordestani, Clinical Cancer Research	2018	96
FDA Approval Summary: Lurbinectedin for the Treatment of Metastatic Small Cell Lung Cancer Sonia Singh, Adnan A. Jaigirdar, Flora Mulkey, Clinical Cancer Research Cancer ManagementPharmacotherapyMetronomic ChemotherapyPre-clinical PharmacologyOncology	2020	88
Osimertinib for the Treatment of Metastatic EGFR T790M Mutation–Positive Non–Small Cell Lung Cancer Sean Khozin, Chana Weinstock, Gideon M. Blumenthal, Clinical Cancer Research	2016	80
Results of a phase 1 trial combining ridaforolimus and MK-0752 in patients with advanced solid tumours Sarina A. Piha‐Paul, P.N. Munster, Antoine Hollebecque, European Journal of Cancer Surgical OncologyMedicineCancer ManagementAdvanced Solid TumoursCancer Treatment	2015	73
FDA Approval Summary: Tucatinib for the Treatment of Patients with Advanced or Metastatic HER2-positive Breast Cancer Mirat Shah, Suparna Wedam, Joyce Cheng, Clinical Cancer Research	2020	62
FDA Approval Summary: Tremelimumab in Combination with Durvalumab for the Treatment of Patients with Unresectable Hepatocellular Carcinoma Timil H. Patel, Jamie R. Brewer, Jiaxin Fan, Clinical Cancer Research PathologyPharmacotherapyClinical TrialsTremelimumab DoseRecommended Tremelimumab Dose	2023	57
U.S. Food and Drug Administration Approval: Cabozantinib for the Treatment of Advanced Renal Cell Carcinoma Harpreet Singh, Michael H. Brave, Julia A. Beaver, Clinical Cancer Research UrologyU.s. FoodGenitourinary CancerMedicineCancer Management	2016	51

Page 1